Estimating the value of SGLT2 inhibitors within the context of contemporary guidelines and totality of evidence.

SGLT2 inhibitors have the potential to lower healthcare costs while improving health outcomes in eligible patient sub-populations. This article is protected by copyright. All rights reserved.